Drugs / RESP30TB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07073638 | Oct 2025 → Sep 2026 overdue | pulmonary tuberculosis | Thirty Respiratory Limited | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RESP30TB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07073638 ↗ |
| Route | Inhaled | “Inhaled RESP30TB 6ml via nebulisation three times daily” NCT07073638 ↗ |